Momelotinib is an excellent example, as it has the potential to overcome the aforementioned challenges for an effective PNPLA3-targeted NASH therapeutic, at clinically tolerable doses. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.